Urolithin A OOS Investigation: QA Decision Guide

An out-of-specification result is a quality event that needs an evidence trail, not an informal request for a more convenient number.

Urolithin A OOS investigation should establish what happened, whether the result is valid, which lot and records may be affected, and who can authorise the final disposition. The investigation must preserve the original data while checking laboratory execution, sample identity, method performance, manufacturing history and supplier information in a controlled sequence.

This guide is for QA reviewers, analytical laboratories, ingredient buyers, contract manufacturers and supplier-quality teams. It explains a two-stage investigation model, retest and resampling boundaries, batch-impact review, supplier communication, root-cause analysis, CAPA and closure evidence. The final procedure should follow the buyer’s approved quality system, quality agreement and destination-market requirements.

Working rule: investigate the original result first; a later passing result does not erase the first result or its data trail.

What an OOS investigation should establish

An OOS result is a result outside an approved specification or acceptance criterion. The investigation should determine whether the result reflects the material, the sampling process, the analytical procedure, a calculation or another assignable cause. It should also assess whether other lots, methods or customers are affected.

The investigation is not complete when a laboratory repeats the test and obtains a passing result. The team must explain the relationship between the original and later data and document the authorised lot decision.

OOS decision map

Stage	Question	Controlled outcome
Detection	What result, limit, method and sample were involved?	OOS record and quality status
Laboratory assessment	Is there a documented execution or data error?	Assignable laboratory cause or full investigation
Manufacturing assessment	Could the material or process explain the result?	Batch-impact and supplier review
Additional testing	Is retesting or resampling scientifically justified?	Approved protocol and interpretation rule
Disposition	What status is authorised for the lot and related stock?	Release, reject, rework, return or continued hold

The Urolithina Lab quality framework can help organize the evidence request, while the buyer’s OOS SOP controls the official investigation.

Place the lot and related material under control

When an OOS result is reported, identify the affected lot, containers, samples, work-in-process, finished products and shipments. Apply the quality status required by the buyer’s procedure and stop an uncontrolled disposition while the review is open.

The status should be visible in physical labels and inventory systems. If material has already moved to another site or customer, record the transfer and escalation path immediately.

Immediate containment fields

• Product, grade, lot, batch and container identifiers.
• Test, method, specification version, result, unit and limit.
• Sample location, sampling date and chain-of-custody reference.
• Current inventory, work-in-process and shipment status.
• Quality status, owner, due date and escalation contact.
• Related lots tested by the same method or process.

Containment does not decide the final outcome. It protects the evidence and keeps the material status aligned with the open investigation.

Preserve original samples and laboratory data

Secure the original sample, preparation solution where stability permits, standards, reagents, vials, chromatograms, instrument files, calculations, worksheets and analyst notes. Record the condition and location of each item before any additional testing.

Do not discard a failed preparation or overwrite a data file because a repeat is planned. If a sample is consumed, damaged or unavailable, document that fact and assess its effect on the investigation.

Evidence-preservation checklist

Evidence	Preservation action	Why it matters
Original sample	Seal, label and record storage condition	Supports later review or authorised resampling
Prepared solution	Record preparation time, hold condition and disposal	Assesses solution stability and repeat validity
Raw data	Lock original files and audit trails	Preserves integration and calculation history
Standards and reagents	Retain lot, expiry and preparation records	Checks response and preparation variables
Instrument status	Save sequence, maintenance and suitability data	Checks system performance at the time of testing

Data preservation should occur before troubleshooting changes the test environment. The original record is the starting point for every later conclusion.

Run the laboratory Phase I assessment

The first phase asks whether the test was executed according to the approved procedure and whether a clear laboratory error invalidates the result. The assessment should be documented by a qualified reviewer who did not simply repeat the test.

Review the sample identity, preparation, calculations, instrument, method, system suitability, analyst training and data processing. If a clear assignable cause is proven, document why the original result is invalid under the procedure and define any required corrective action.

Phase I review questions

1. Was the correct sample, lot and container tested?
2. Were the current method and specification used?
3. Were weights, dilutions, units and calculations transcribed correctly?
4. Did blanks, standards, spikes and system-suitability checks meet criteria?
5. Was the instrument calibrated, maintained and within status?
6. Were sample and standard solutions within the allowed hold time?
7. Did the analyst follow the procedure and record any deviation?
8. Is there objective evidence of an assignable laboratory error?

A suspicion is not the same as a demonstrated error. “The result looks unusual” is a reason to investigate further, not a reason to discard it.

Check sample identity and preparation

Sample errors can arise before the instrument run. Confirm the lot, container, sampling location, label, mass, solvent, extraction, mixing, filtration, dilution and hold time. For a powder, check whether the portion was representative and whether moisture or agglomeration could influence preparation.

Compare the original preparation with the approved method and the analyst’s worksheet. A correct calculation applied to a wrong sample remains an invalid release basis.

Sample-preparation review

Review point	Evidence	Possible finding
Identity	Sample label, lot, container and request	Wrong lot or mixed sample
Weighing	Balance ID, status, mass and record	Transcription or balance issue
Extraction	Solvent, time, mixing and temperature	Incomplete or inconsistent recovery
Filtration	Filter type, rinse and sample appearance	Adsorption, blockage or contamination
Hold time	Preparation and injection timestamps	Solution change before analysis

If no preparation error is demonstrated, retain the original result and continue to the full investigation.

Review method, instrument and system suitability

Inspect the method version, column or instrument configuration, detector settings, calibration, blank, standard response, replicate precision, resolution, carryover and integration. Compare the actual sequence with the method’s required sequence.

For physical or microbiological tests, review the corresponding equipment, environment, sample condition and method controls. An OOS process should cover all attributes, not only chromatographic assays.

Instrument and method checks

• Method and specification revisions were current.
• Instrument qualification, calibration and maintenance were in status.
• System-suitability criteria were defined and met or investigated.
• Blank, standard, spike and control results were acceptable.
• Integration, calculation and rounding followed the procedure.
• Any instrument alarm, interruption or reprocessing is documented.

When a system-suitability failure occurs, determine which results are affected before deciding whether an OOS result can be invalidated.

Decide whether a clear laboratory cause exists

A laboratory cause should be supported by objective evidence such as a documented wrong dilution, failed system suitability, instrument malfunction or confirmed sample mix-up. The investigation should state how the cause explains the original result and whether other samples or lots are affected.

If a cause is not proven, do not label the OOS as laboratory error simply because a later result passes. Continue to the manufacturing and process assessment.

Assignable-cause table

Potential cause	Evidence that may support it	Required decision
Calculation or transcription	Original worksheet, formula and verified correction	Assess affected reports and reissue control
Instrument failure	Alarm, maintenance, suitability or calibration record	Assess sequence validity and affected samples
Preparation error	Deviation, analyst interview and independent reconstruction	Determine whether original result is invalid
Sample mix-up	Label, chain-of-custody or container evidence	Review all related samples and lots
No assignable cause	Phase I review complete without proof of error	Continue full investigation; retain original result

Document the decision in the OOS record, with the reviewer and approval date. A verbal conclusion is not sufficient for a release file.

Open the manufacturing and supplier Phase II investigation

Phase II examines whether the material or process could explain the result. Review batch records, raw-material lots, process parameters, yields, equipment status, cleaning, hold times, packaging, storage, deviations, previous lots and supplier communications.

For an incoming Urolithin A lot, include the supplier’s COA, specification, sampling record, change history and any independent testing. Ask the supplier to preserve its original data and investigate through its own quality system.

Phase II review fields

• Manufacturing and packing lot records.
• Starting-material and solvent lots.
• Process parameters, yield and material balance.
• Equipment, cleaning, calibration and maintenance status.
• Storage, transport, package and temperature history.
• Previous and subsequent lot trends.
• Supplier changes, deviations, complaints and CAPA.

Phase II should explain whether the result is isolated, lot-specific, process-related, method-related or still unresolved.

Set a retest plan before generating more data

Retesting should answer a defined question and follow a written protocol. State the number of preparations or injections, analyst, method, sample source, acceptance rule and interpretation before testing begins.

A retest is not a search for a passing result. If the original result remains valid and the retest differs, the investigation must explain the variation and decide how both sets of data affect the lot.

Retest-plan fields

Field	Define before retest	Why it matters
Purpose	Question the retest is intended to answer	Avoids unstructured repeat testing
Sample	Original preparation, reserve or new portion	Shows what source the result represents
Method	Version, analyst, instrument and controls	Ensures a comparable result
Number	Preparations, injections and sequence	Prevents changing the plan after results appear
Interpretation	How original and retest results will be evaluated	Keeps disposition evidence-based

Record the retest protocol and approval in the OOS file. If the method or sample changes, explain why and assess comparability.

Distinguish retesting from resampling

Retesting uses the original sample or preparation under an approved plan. Resampling takes a new portion from the lot. The two actions answer different questions and carry different assumptions about representativeness.

Resampling may be appropriate when the original sample was not representative or a documented sampling issue exists. It should not be used merely because the first result is inconvenient.

Retest and resample comparison

Action	Question answered	Control needed
Repeat injection	Was instrument response or injection precision involved?	Sequence and system-suitability review
New preparation	Was sample preparation variation involved?	Independent preparation and protocol
Resample same container	Was the first portion unrepresentative?	Sampling rationale and location record
Resample other containers	Is the result container-specific or lot-wide?	Expanded sampling plan and disposition rule

Never combine retest and resample results in one average without a documented statistical and quality rationale.

Evaluate batch impact and related lots

Determine whether the OOS result affects only the tested lot or also other lots, products, customers, methods or time periods. Review common raw materials, equipment, process changes, analytical runs and storage conditions.

For a supplier result, ask whether other customers received the same lot and whether a corrected COA or notification is required. For a manufacturing result, check work-in-process and finished batches that used the material.

Impact-assessment fields

• Tested lot and all containers represented.
• Related lots made before and after the event.
• Shared raw materials, equipment, method, analyst or laboratory.
• Shipments, production batches and customer destinations.
• Existing complaints, trends, deviations or changes.
• Additional testing, notification and disposition needs.

Document the scope even when no additional impact is found. “No impact” is a conclusion that needs a review basis.

Communicate with the supplier and laboratory

Supplier communication should state the lot, result, method, limit, sample, status and requested response. Ask for original records and an investigation summary, not only a replacement certificate.

Keep communications in the controlled OOS file. If the supplier proposes retesting, confirm that the buyer’s procedure and quality agreement allow the plan and define who approves it.

Supplier OOS request

1. Identify product, lot, container and test field.
2. Attach the result, method, limit and sample reference.
3. State the current quality status and containment action.
4. Request the supplier’s original data, investigation and batch impact.
5. Define the response deadline and required approval.
6. Record any corrected COA or customer notification under revision control.

For a structured file request, use the quality-file request form and include the destination market and product stage.

Use a formal root-cause method

Once the facts are assembled, use a structured root-cause method such as a cause-and-effect diagram, fault tree, five-whys analysis or process mapping. The method should distinguish direct error, contributing condition and system weakness.

A root cause should explain the evidence and predict what would change if the action works. “Operator error” is incomplete when the procedure, training, interface or workload made the error likely.

Root-cause questions

• What changed from the expected process or method?
• Was the change detectable before the result was reported?
• Did the procedure and equipment support the required action?
• Were similar lots or tests exposed to the same condition?
• What evidence rules out alternative causes?
• How will effectiveness be measured after the action?

Keep factual evidence separate from hypotheses in the investigation report. Mark open questions and assign owners rather than presenting assumptions as conclusions.

Define CAPA and effectiveness checks

Corrective action addresses the cause of the event. A preventive system improvement may address a related weakness identified by the investigation. Actions can include method revision, equipment repair, sampling redesign, training, supplier change, software control or specification clarification.

Each action needs an owner, due date, approval and effectiveness measure. Closing a CAPA because a procedure was issued is not enough if the next lots do not show improvement.

CAPA evidence table

CAPA element	Example evidence	Effectiveness check
Method	Revised procedure, verification and analyst training	Subsequent runs meet controls
Sampling	New locations, tools or composite rule	Representative results across lots
Equipment	Repair, calibration or configuration change	Maintenance and performance records
Supplier	Process action, change notification or audit	First-lot and trend review
System	Training, software control or approval change	Record review and recurrence monitoring

Link CAPA to the OOS, deviation, supplier record and affected lots. Separate immediate correction from long-term system action.

Close the OOS investigation with a documented disposition

The final report should summarize the original result, evidence reviewed, laboratory and manufacturing assessments, additional testing, root cause, batch impact, CAPA and disposition. It should explain why the conclusion follows from the data.

Possible dispositions include release when the result is proven invalid under procedure, rejection, return, rework, additional controlled testing or continued hold. The authorised approver should sign and date the decision.

Closure checklist

1. Original result and records are preserved.
2. Phase I and Phase II assessments are complete or justified.
3. Retest or resample data are linked and interpreted.
4. Related lots, products and customers were assessed.
5. Root cause and CAPA owners are documented.
6. Disposition and status changes are authorised.
7. Effectiveness and trend follow-up are scheduled.

An investigation can close with an unresolved root cause if the lot decision and follow-up controls are clear. It should not close by deleting the original OOS from the record.

Trend OOS events across lots and laboratories

One OOS event may be isolated; repeated near-limit or failed results may reveal a process, method, supplier or sampling trend. Review events by product, lot, test, laboratory, analyst, instrument, supplier and cause.

Trend review should include invalidated results and laboratory investigations. Removing an event from the trend because it was later invalidated can hide a recurring weakness in sample preparation or system control.

Trend fields

Trend dimension	Record	Use
Material	Product, grade, lot and supplier	Identify supply or process patterns
Test	Attribute, method, limit and result	Find method-specific movement
Laboratory	Site, instrument, analyst and date	Check laboratory contribution
Cause	Assignable, process, sampling or unresolved	Prioritise system action
Outcome	Disposition, CAPA and effectiveness	Assess whether actions worked

Use the technical resources page to organize recurring quality records, while keeping the formal OOS file under document control.

Use regulatory guidance within its scope

The FDA OOS investigation guidance provides a useful reference for laboratory and full investigations. Apply the current version and adapt the process to the buyer’s material, market and quality system.

For U.S. dietary-supplement records, 21 CFR 111.95 describes records within that specific framework. Neither reference removes the need for a product-specific specification, quality agreement and authorised disposition.

Build an OOS evidence package

The OOS file should allow another qualified reviewer to reconstruct the event. Include the original result, sample and raw data, method and specification, Phase I and Phase II records, additional testing, supplier communication, impact assessment, CAPA and final disposition.

OOS-file index

File	Minimum content	Purpose
Initial record	Lot, test, result, limit, method and status	Defines the event
Laboratory data	Sample, preparation, sequence, raw data and review	Supports Phase I
Manufacturing review	Batch, process, equipment and supplier evidence	Supports Phase II
Additional testing	Protocol, results and interpretation	Shows how later data were used
CAPA	Root cause, action, owner and effectiveness	Addresses recurrence
Disposition	Impact, approval, date and status	Closes the quality decision

Link the file to the incoming lot, supplier record and finished-product batches where relevant. Keep the original OOS visible in the history even when the final conclusion identifies a laboratory cause.

Build a buyer-side OOS scorecard

A scorecard helps QA assess whether a supplier or contract laboratory handles OOS events with discipline. Score the investigation process and evidence, not simply the final lot outcome.

OOS evidence scorecard

Area	Strong evidence	Conditional evidence	Gap
Containment	Lot, stock and status are controlled promptly	Containment complete with minor delay	Material moved without status
Data preservation	Original samples, raw data and audit trail retained	Some reserve material unavailable with assessment	Failed data overwritten or discarded
Phase I	Execution, method and instrument reviewed objectively	Laboratory review open with owner	Result dismissed without evidence
Phase II	Batch, supplier and related lots assessed	Limited scope with rationale	No manufacturing assessment
Additional testing	Protocol and interpretation defined in advance	Retest justified after review	Testing repeated until pass
Closure	Root cause, CAPA, impact and disposition approved	CAPA open with monitoring	No accountable conclusion

Use the scorecard to compare supplier and laboratory practices. It does not replace the buyer’s OOS SOP, quality agreement, validated methods or market review.

Frequently asked questions about Urolithin A OOS investigations

Can a passing retest invalidate an OOS result?

Not by itself. The investigation must explain the original result, establish an assignable cause or evaluate both data sets under an approved interpretation rule.

When is resampling appropriate?

Resampling may be justified when the original sample was not representative or a documented sampling issue exists. The reason, locations, number of portions and acceptance rule should be approved before new testing.

Should the supplier receive the original OOS result?

When the supplier’s lot or process may be involved, share the controlled result and request an investigation through the quality agreement. Preserve the buyer’s original records and status.

What if no root cause is found?

The investigation can close with an unresolved cause when the data, lot impact, disposition and follow-up controls are documented. Unresolved events should remain visible in trend review.

Can a buyer average original and retest results?

Not without a documented technical and statistical rationale. Averaging can hide a failed result and is not a substitute for determining why the results differ.

Does an OOS event always mean the lot must be rejected?

No. The authorised disposition depends on the validity of the result, investigation evidence, specification, lot impact and quality-system rules. The lot remains under the defined status until that decision is made.

How long should an OOS record be retained?

Use the buyer’s record-retention rule, quality agreement and market requirements. Retain enough information to reconstruct the result, investigation, disposition and CAPA after the lot is no longer in inventory.

Turn an OOS result into a controlled quality decision

A defensible Urolithin A OOS investigation preserves the first result, protects the lot status, reviews laboratory and manufacturing evidence, controls additional testing and documents the final disposition. The purpose is not to find a passing number; it is to understand the event and make a decision that another qualified reviewer can follow.

Before closing an OOS, confirm the original data, sample, method, specification, impact assessment, supplier response, CAPA and authorised disposition are linked. For a lot-specific review, use the quality-file request form and include the destination market, product stage and records your quality system requires.

Scope note: This article is a B2B ingredient-quality framework. It does not replace the buyer’s approved OOS procedure, validated methods, quality agreement, regulatory assessment or finished-product release system.